JMP Securities restated their market outperform rating on shares of CureVac (NASDAQ:CVAC - Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $16.00 price target on the stock.
CureVac Stock Down 4.9 %
Shares of CVAC stock traded down $0.17 during trading hours on Monday, hitting $3.27. 428,613 shares of the company were exchanged, compared to its average volume of 942,643. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.28 and a current ratio of 2.29. The stock has a market capitalization of $732.09 million, a price-to-earnings ratio of -2.46, a P/E/G ratio of 2.15 and a beta of 2.62. CureVac has a one year low of $2.21 and a one year high of $8.04. The business's 50-day simple moving average is $3.33 and its two-hundred day simple moving average is $3.28.
CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). CureVac had a negative return on equity of 57.18% and a negative net margin of 422.66%. The firm had revenue of $15.55 million for the quarter, compared to the consensus estimate of $10.07 million. Sell-side analysts predict that CureVac will post 0.05 EPS for the current fiscal year.
Institutional Trading of CureVac
Institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. acquired a new stake in shares of CureVac during the 2nd quarter worth approximately $8,237,000. Platinum Investment Management Ltd. increased its position in CureVac by 25.9% in the first quarter. Platinum Investment Management Ltd. now owns 626,684 shares of the company's stock worth $1,899,000 after buying an additional 128,778 shares during the period. Jump Financial LLC acquired a new position in shares of CureVac during the fourth quarter valued at $346,000. Tidal Investments LLC acquired a new position in shares of CureVac during the first quarter valued at $175,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of CureVac by 45.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 44,122 shares of the company's stock worth $184,000 after acquiring an additional 13,687 shares during the last quarter. Institutional investors own 17.26% of the company's stock.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
